7 Best Peptides for Hearing Loss

What to Know Before Choosing a Peptide for Hearing Loss

Hearing loss sits at one of the harder edges of regenerative medicine. The cochlear hair cells that convert sound into electrical signals do not grow back once they are gone in humans, and that biological reality has driven decades of pharmaceutical research without, so far, producing a single approved peptide therapy. Anyone arriving at this topic is working in genuinely experimental territory, and this guide is built around that honest framing rather than a cleaner story that does not exist.

A peptide earns a slot in this guide because people use it or are actively discussing using it for hearing loss. That is the whole test. FDA-approved, telemedicine-prescribed, and research-only compounds are all eligible. A compound with only community-reported anecdotal use still belongs here, with its thin evidence stated plainly. The aim is not to suggest these compounds are equivalent but to give you an honest map of what the field actually looks like rather than a quietly filtered list that only shows what someone could defend in a clinical meeting.

The compounds below are numbered by how prominently each appears in research and real-world discussion, not as a recommendation of one over another. Position one does not mean use this one first. It means this compound has the deepest research trail in the context of hearing loss. The right option for any individual depends on factors the app is built to help work through, not on where a compound lands in a list.

1. D-JNKI-1 (Brimapitide): The Most Clinically Tested Candidate

D-JNKI-1, developed under the clinical names AM-111 and Brimapitide and at one point intended for the brand name Sonsuvi, is the peptide that advanced furthest in formal clinical development for hearing loss. It is a cell-permeable peptide built to block the JNK signaling cascade, one of the key molecular death pathways that cochlear hair cells travel down after acoustic trauma or exposure to ototoxic drugs. When the inner ear is damaged by loud noise or by aminoglycoside antibiotics like gentamicin, a chain of molecular events unfolds that ends in hair cell apoptosis, which is programmed cell death. D-JNKI-1 was designed to interrupt that chain early enough to prevent the apoptosis from completing. The peptide uses a Tat transporter sequence, derived from an HIV-1 protein, to cross into sensory cells, and it is delivered by intratympanic injection, meaning directly into the middle ear space, where it permeates the round window membrane into the cochlea.

The clinical trial history matters and is worth knowing in full. A Phase 2 trial produced genuinely encouraging results, showing statistically significant hearing improvement specifically in patients with severe-to-profound sudden sensorineural hearing loss, those with a threshold loss of 60 decibels or greater. People with milder sudden hearing loss tend to recover spontaneously at high rates, which muddied the broader study results, so the benefit concentrated in that severe subset. The Phase 2 data established a real proof of concept. Then came two Phase 3 trials. The European Phase 3 enrolled 256 patients and failed its primary efficacy endpoint. The North American Phase 3 was terminated before completion. The developing company, Auris Medical, which later rebranded as Altamira Therapeutics, discontinued the program. D-JNKI-1 received both FDA Fast Track Designation and Orphan Drug Designation during development, but neither of those designations confers approval, and the compound is not commercially available and is not prescribed through any telemedicine platform.

What this entry represents is the field's most serious attempt to bring a peptide to clinical use for hearing loss, and an honest record of how that attempt ended. The mechanism is well-characterized, the Phase 2 signal was real, and the Phase 3 failure means it did not clear the efficacy bar required for approval in that trial design and patient population. For anyone following hearing loss research, D-JNKI-1 is the reference point against which other compounds are understood.

2. HNG and SHLP3: Mitochondrial-Derived Peptides for Ototoxic Damage

Humanin (HNG) and Small Humanin-Like Peptide 3 (SHLP3) belong to a class called mitochondrial-derived peptides, encoded within the mitochondrial genome itself rather than the nuclear genome, which makes them a genuinely novel drug class. Their relevance to hearing loss comes from a 2024 study published in Nature Cell Death and Disease, which demonstrated that both peptides protect cochlear hair cells from gentamicin-induced damage in cell cultures and in mouse models.

The mechanisms differ between the two compounds in useful ways. HNG activates STAT3, ERK1/2, and AKT signaling pathways, reduces the production of reactive oxygen species, and counteracts the apoptotic cascade that aminoglycoside antibiotics trigger in hair cells. Think of those activated pathways as survival switches that HNG flips on inside the cell to offset the death signal the drug creates. SHLP3 works through AMPKα activation, a cellular energy-sensing pathway that acts somewhat like a metabolic alarm system, alongside AKT and anti-inflammatory signaling. Together, in the 2024 study, they attenuated gentamicin-induced apoptosis, reduced oxidative stress, and suppressed inflammatory cytokine release.

The evidence here is limited to cell and mouse models as of 2026. No human clinical trial has been published for either compound in hearing loss, and no clinical development program has been announced. HNG and SHLP3 belong in this list because they represent the direction the basic science is moving, and because the mitochondrial-derived peptide class is attracting genuine research attention for ototoxic hearing loss specifically.

3. GV1001: For Ototoxic and Noise-Damaged Hair Cells

GV1001 has an unusual backstory for a hearing loss compound. It was originally developed as an anticancer peptide vaccine targeting telomerase, a protein cancer cells use to extend their abnormal lifespan. That application did not succeed, but the development process accumulated safety data and established that GV1001 has meaningful anti-inflammatory and antioxidant properties. Those properties brought it into hearing loss research, where it was tested in mouse models of ototoxic deafness using kanamycin and furosemide.

The mechanism GV1001 operates through for hearing loss involves inhibiting p38 MAPK and NF-kB signaling, two of the major inflammatory amplification routes active in a damaged cochlea, reducing the cytokine cascade that worsens hair cell injury after an ototoxic event. The compound also reduces oxidative stress and shows anti-apoptotic effects through the combined result of those actions. What made the animal research particularly notable was a timing finding: GV1001 demonstrated restoration of hearing even when given up to three days after the ototoxic injury. Most hair cell protection strategies require intervention during or immediately after the damaging event, so a three-day window is a meaningful result if it translates to humans.

That translation has not been established. As of 2026, GV1001 has no published human clinical trial data for hearing loss. The animal evidence is published in peer-reviewed literature, and the compound's prior development as a cancer vaccine candidate means there is some existing human safety data from that context, which is more than many experimental compounds in this space can claim. It does not speak to the hearing loss application specifically, but it is a useful starting point.

4. PS-pep: For Ischemia-Related Cochlear Damage

PS-pep is an 18-amino acid peptide derived from prosaposin, a lysosomal protein with a neurotrophic region studied for neuroprotective effects. Its relevance to hearing loss is narrow and specific: it targets ischemia-induced cochlear damage, meaning the hair cell death that follows a transient interruption of blood supply to the cochlea. That is a distinct subtype from noise-induced or ototoxic damage, and PS-pep's mechanism is correspondingly specific. It activates anti-apoptotic pathways and increases expression of Bcl-2, a key anti-cell-death protein, in inner hair cells, preventing the apoptosis that cochlear ischemia would otherwise trigger. Think of Bcl-2 as a cellular dam that holds back the flood of apoptotic signals; PS-pep helps build that dam before the ischemic event can breach it.

The research has been conducted in guinea pig and mouse models. No human trial data exists as of 2026. The compound's narrow target means it is not a broad-spectrum hearing loss candidate. It was developed for one mechanism of cochlear injury, and that specificity is scientifically useful while also limiting how widely applicable it would be even if it progressed through clinical development.

PS-pep appears here because the published animal evidence is substantive and because ischemia-related hearing loss is a real and underserved clinical problem. People researching the preclinical inner ear therapeutic pipeline will encounter it, and understanding where it fits in the landscape is useful context.

5. P13: An Anti-Inflammatory Approach via Ear Drops

P13, also referenced as P13T1, is an anti-inflammatory peptide developed specifically for noise-induced and blast-induced hearing loss. What distinguishes it from most other compounds in this space is the delivery method: P13 is formulated as ear drops designed to cross the intact tympanic membrane and reach the inner ear without injection. That is a significant practical advantage, because most peptide delivery approaches for the cochlea require either intratympanic injection or more invasive routes. A compound that works as ear drops would be far more accessible to patients if it progresses.

The research on P13 has been conducted in mouse models of noise-induced hearing loss and in blast-injury preclinical models funded by the U.S. Department of Defense blast injury research program. That military funding reflects a genuine operational need: a treatment that can be rapidly self-administered by personnel after acoustic blast exposure, where the protective window is measured in hours. The animal data shows P13 reducing noise-induced threshold shifts, meaning it appears to limit the degree of permanent hearing elevation after damaging noise exposure when given in that window.

As of 2026, P13 remains preclinical with no published human trial. The compound is not commercially available, and community discussion of it specifically is limited. The published animal evidence and active military research program make it a compound worth knowing in any honest survey of the peptide hearing loss landscape.

6. BPC-157: Widely Discussed, No Hearing-Specific Evidence

BPC-157 is one of the most widely discussed peptides in the biohacking and research communities, and that conversation extends into hearing loss and tinnitus discussions despite the compound having no published clinical trials or animal studies that directly test it on cochlear tissue or hearing thresholds. The theoretical basis people cite for its potential is drawn from mechanisms established in other tissues: BPC-157 promotes angiogenesis through VEGF upregulation, which could theoretically improve blood supply to the stria vascularis, the structure in the cochlea responsible for maintaining the precise ionic environment that hearing depends on. It also shows neuroprotective properties in peripheral tissue models, which some users extrapolate to potential auditory nerve support.

The evidence for BPC-157 in hearing loss is experiential rather than clinical, and the community experience is mixed to negative overall. One user on a tinnitus forum reported a 30 to 35 percent reduction in tinnitus in one ear, attributed it to nerve regeneration, and acknowledged the day-one improvement might have been a coincidence. That is the most positive account in the available community record. The general pattern across Reddit discussions covering tinnitus and hearing loss is that most users report no benefit. Some have reported significant adverse reactions, including worsening of pre-existing inflammatory conditions, though those reports cannot be definitively attributed to BPC-157 in the absence of controlled data.

No human clinical trial has been published for BPC-157 in hearing loss as of 2026. No animal study has directly tested it on cochlear hair cells or hearing thresholds. The compound is available as a research chemical through online suppliers, is not approved for any indication, and any use for hearing loss exists entirely outside established protocols. People discuss it because BPC-157 is one of the most recognized peptides in the community and because the cochlear blood supply hypothesis is intuitive even if unsubstantiated. That discussion is why it belongs in this list.

7. Cerebrolysin: For Auditory Nerve Support via Neurotrophic Factors

Cerebrolysin is a peptide-based preparation derived from purified porcine brain proteins that contains a mixture of low-molecular-weight neuropeptides alongside naturally occurring neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). It is approved in some European, Commonwealth of Independent States, and Asian countries for neurological conditions including stroke recovery, Alzheimer's disease, and traumatic brain injury. It is not FDA-approved and is not available through standard US prescribers, though it can be obtained through international pharmacies or compounding channels in some regions.

The theoretical connection to hearing loss runs through its neurotrophic factors. BDNF in particular has an established role in maintaining the ribbon synapses between inner hair cells and spiral ganglion neurons, the auditory neurons that connect the cochlea to the brain. When those synapses degrade without the overt hair cell death that shows up on a standard audiogram, the result is cochlear synaptopathy, sometimes called hidden hearing loss. The logic for Cerebrolysin in this context is that its BDNF and NGF content could support spiral ganglion neuron survival and potentially help preserve or restore those synaptic connections. Its anti-apoptotic and anti-neuroinflammatory properties, well-established in the neurological literature, are theoretically applicable to the same pathways that cause cochlear damage.

No human clinical trial has been published for Cerebrolysin in hearing loss as of 2026, and no animal study has directly tested it on hearing outcomes. Community discussion of Cerebrolysin for hearing specifically is limited compared to its broader use in cognitive and neurological protocols. The relevance here is theoretical extrapolation from a well-characterized neurological compound rather than an established hearing loss application. Its BDNF content gives the theoretical case more substance than many compounds in this space can claim, even without hearing-specific evidence to support it.

How These Peptides Compare

Frequently Asked Questions

Is any peptide proven to restore hearing?

No peptide is currently FDA-approved or clinically recommended for treating any form of hearing loss. D-JNKI-1 came closest, showing meaningful results in a Phase 2 trial for severe sudden hearing loss, but it failed in Phase 3 trials and is no longer in active development. Every other compound in this field remains preclinical or is used without any formal evidence base for this specific application.

Are these peptides available to buy or use right now?

That depends on the compound. D-JNKI-1 was a clinical drug candidate and is not available for purchase or prescription. HNG, SHLP3, PS-pep, P13, and GV1001 are all preclinical research compounds with no commercial availability. BPC-157 is available as a research chemical through online suppliers, though it is unregulated and not approved for human use in this context. Cerebrolysin is available through international or compounding pharmacies in some regions, approved for neurological conditions there, though it carries no approved hearing loss indication anywhere.

Why is the evidence for hearing loss peptides so limited?

The cochlea sits within the densest bone in the body, its fluid environment is precisely regulated, and getting any compound to the hair cells in meaningful concentrations without causing additional damage is a significant delivery problem. Beyond access, cochlear hair cells in mammals do not regenerate, which means the window for any protective intervention is narrow, often hours to days after the damaging event, and clinical trial design around acute hearing loss is genuinely difficult. Those structural challenges explain why the field has moved slowly despite real scientific interest.

How does peptide research for hearing loss compare to gene therapy?

Gene therapy for hearing loss recently reached FDA approval for a specific genetic form of the condition involving mutations in the OTOF gene. That approach delivers a corrected gene to restore a lost biological function. Peptide approaches aim instead to protect cells from damage or support their survival during an injury window rather than correcting a genetic deficit. The two approaches target different causes and different patient populations, and neither makes the other obsolete.

Should someone with hearing loss consider trying these compounds?

That is a clinical question that belongs with a healthcare provider who knows the individual's full history. What this guide offers is the honest picture of where the evidence stands: mostly preclinical, partly anecdotal, and not yet at a threshold where any compound can be recommended for routine use. Anyone considering experimental options for hearing loss would benefit from speaking with an otolaryngologist as part of that conversation.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for hearing loss in one place.